ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "NeoStem, Inc." (NBS) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"NeoStem, Inc." (NBS)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: CBMG, MDXG, MACK, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"NeoStem, Inc."© quotemedia

Company Profile

NeoStem, Inc., a biopharmaceutical company, engages in the development of proprietary cellular therapies in cardiovascular disease, immunology, and regenerative medicine primarily in the United States. The company is involved in collecting, storing, manufacturing, therapeutic developing, and transporting cells for cell based medicine and regenerative science. It also provides clinical trial design support, logistics, and quality systems development services; adult stem cell collecting, processing, and storing services, which enable individuals to donate and store their stem cells for personal therapeutic use; and contract manufacturing, product and process developing, regulatory consulting, product characterization, and comparability services. In addition, the company collects and stores cord blood cells of newborns. Further, its product candidate includes AMR-001, a chemotactic hematopoietic stem cell product, which is in Phase II trials to treat damaged heart muscle following acute myocardial infarction. Additionally, the company, in collaboration with Becton-Dickinson, is involved in the research and development of a T-cell therapy for autoimmune conditions. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

Recent News: "NeoStem, Inc."